Skip to main content
SpringerLink
Log in

Lamifiban

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Lamifiban is an intravenously administered, selective, reversible, nonpeptide glycoprotein IIb/IIIa receptor antagonist which inhibits platelet aggregation and thrombus formation by preventing the binding of fibrinogen to platelets.

  • ▴ In trials in patients with non-Q wave myocardial infarction (MI) or unstable angina pectoris (PARAGON A and the Canadian Lamifiban Study), the incidence of clinical events at 30 days in patients receiving lamifiban (1 to 5 µg/min) was not significantly different from that in patients receiving aspirin plus heparin or aspirin alone.

  • ▴ In PARAGON A, the incidence of clinical events at 6 months was significantly lower after lamifiban (with or without heparin) and aspirin therapy than after standard heparin and aspirin therapy.

  • ▴ A large phase III trial (PARAGON B) is under way comparing lamifiban plus aspirin and heparin with standard aspirin and heparin therapy in patients with non-Q wave MI or unstable angina pectoris.

  • ▴ In clinical trials, the most common adverse events associated with lamifiban were bleeding complications which were increased by the concomitant administration of heparin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ro 44-9883 (Lamifiban) Platelet aggregation inhibitor. Investigational Drug Brochure, F. Hoffman-La Roche, 1997

  2. News from the XVIIIth congress of the European Society of Cardiology. Br J Cardiol 1996; 3(5): 154–5

    Google Scholar 

  3. Dagenais P, Libersan D, Merhi Y, et al. GPIIb/IIIa receptor blockade at reperfusion by lamifiban reduces infarct size in the dog [abstract]. Can J Cardiol 1997 Sep; 13 Suppl. C: 94–5

    Google Scholar 

  4. Takiguchi Y, Asai F, Wada K, et al. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Thromb Haemost 1995 Apr; 73(4): 683–8

    PubMed  CAS  Google Scholar 

  5. Théroux P, Kouz S, Roy L, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation 1996 Sep 01; 94: 899–905

    Article  PubMed  Google Scholar 

  6. PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Card. In press

  7. Becker RC, Ali O, Harrington RA, et al. Platelet inhibition with the glycoprotein IIb/IIIa receptor antagonist lamifiban in high risk patient subsets: studies to determine the correlation between platelet-mediated prothrombotic activity and clinical risk [abstract]. Circulation 1997 Oct 21; 96 Suppl.: 748

    Article  Google Scholar 

  8. Lehne G, Nordal K, Midtvedt K, et al. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. Thromb Haemost 1998; 79: 1119–25

    PubMed  CAS  Google Scholar 

  9. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 1998 Jun; 97: 2386–95

    Article  Google Scholar 

  10. Steiner B, Hofer U, Wittke B, et al. Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A [abstract]. Eur Heart J 1998 Aug; 19: 598

    Google Scholar 

  11. Lave T, Saner A, Coassolo P, et al. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 1996; 48: 573–7

    Article  PubMed  CAS  Google Scholar 

  12. Moliterno DJ, Harrington RA, Newby K, et al. Pronounced reduction in long-term ischemic events with platelet IIb/IIIa antagonism among diabetics with unstable angina: PARAGON 6-month results [abstract]. Circulation 1997 Oct 21; 96 Suppl.: 474

    Google Scholar 

  13. Topol EJ, Califf R, Van der Werf F. The PARAGON B trial: a randomized, double-blind, placebo-controlled study of lamifiban (Ro 44-9883) in patients with unstable angina/non-Q wave myocardial infarction. Hoffmann-La Roche, 1997

  14. Adgey AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Am Heart J 1998 Apr; 135: S43–55

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Mukta Dooley & Karen L. Goa

Authors
  1. Mukta Dooley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mukta Dooley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dooley, M., Goa, K.L. Lamifiban. Drugs 57, 215–221 (1999). https://doi.org/10.2165/00003495-199957020-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957020-00009

Keywords

Search

Navigation